Dr. Black on Combinations with Durvalumab in Bladder Cancer

Peter Black, MD
Published Online: Tuesday, May 16, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Durvalumab works as a monotherapy for the second-line setting after cisplatin therapy, explains Black. In the first-line setting there is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy.

In other disease sites, the combination works well—making people very optimistic but the results will take a few years, states Black.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Durvalumab works as a monotherapy for the second-line setting after cisplatin therapy, explains Black. In the first-line setting there is a combination trial of durvalumab versus durvalumab plus tremelimumab versus standard chemotherapy.

In other disease sites, the combination works well—making people very optimistic but the results will take a few years, states Black.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x